| Cash Flow | 2025-08-31 |
|---|---|
| Net (loss) income | -5,540 |
| Amortization and depreciation | 4 |
| Stock-based compensation | 179 |
| Prepaid expenses and other assets | -1,989 |
| Accounts payable, accrued expenses, and other liabilities | 918 |
| Net cash (used in) provided by operating activities | -2,450 |
| Proceeds from exercise of stock options | 21 |
| Cash paid for note payable | 142 |
| Net cash (used in) provided by financing activities | -121 |
| Net change in cash and cash equivalents | -2,571 |
| Cash and cash equivalents at beginning of period | 11,903 |
| Cash and cash equivalents at end of period | 9,332 |
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)